Display options
Cite
Ghandour M, Hashim A, Yassin AS, et al. Progressive Multifocal Leukoencephalopathy Secondary to Adalimumab. Am J Ther. 2020;28(6):e748-e750doi: 10.1097/MJT.0000000000001188.
Ghandour, M., Hashim, A., Yassin, A. S., ELJack, A., Shereef, H., Mohamed, K., Elshekhidris, A., & Singer, D. (2020). Progressive Multifocal Leukoencephalopathy Secondary to Adalimumab. American journal of therapeutics, 28(6), e748-e750. https://doi.org/10.1097/MJT.0000000000001188
Ghandour, Mohamedanwar, et al. "Progressive Multifocal Leukoencephalopathy Secondary to Adalimumab." American journal of therapeutics vol. 28,6 (2020): e748-e750. doi: https://doi.org/10.1097/MJT.0000000000001188
Ghandour M, Hashim A, Yassin AS, ELJack A, Shereef H, Mohamed K, Elshekhidris A, Singer D. Progressive Multifocal Leukoencephalopathy Secondary to Adalimumab. Am J Ther. 2020 Apr 23;28(6):e748-e750. doi: 10.1097/MJT.0000000000001188. PMID: 32341263.
Copy Download .nbib Format: NLM
Share it on

Am J Ther. 2020 Apr 23;28(6):e748-e750. doi: 10.1097/MJT.0000000000001188.

Progressive Multifocal Leukoencephalopathy Secondary to Adalimumab.

American journal of therapeutics

Mohamedanwar Ghandour, Ahmed Hashim, Ahmed S Yassin, Ammar ELJack, Hammam Shereef, Khalid Mohamed, Abid Elshekhidris, Daniel Singer

Affiliations

  1. Department of Nephrology, DMC/Wayne State University, Detroit, MI.
  2. Internal Medicine, Beaumont Hospital, Dearborn, MI.
  3. Internal Medicine, Wayne State University/DMC, Detroit, MI.
  4. Internal Medicine, The National Ribat University, Khartoum, Sudan.
  5. Director of Neurology Department, Beaumont Hospital, MI.

PMID: 32341263 DOI: 10.1097/MJT.0000000000001188

[No abstract available.]

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

  1. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9:425–437. - PubMed
  2. Rockwell D, Ruben FL, Winkelstein A, et al. Absence of imune deficiencies in a case of progressive multifocal leukoencephalopathy. Am J Med. 1976;61:433–436. - PubMed
  3. Fermaglich J, Hardman JM, Earle KM. Spontaneous progressive multifocal leukoencephalopathy. Neurology 1970;20:479–484. - PubMed
  4. Power C, Gladden JG, Halliday W, et al. AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology 2000;54:743–746. - PubMed
  5. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 2009;60:3761–3765. - PubMed
  6. Wenning W, Haghikia A, Laubenberger J, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med. 2009;361:1075–1080. - PubMed
  7. Linda H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med. 2009;361:1081–1087. - PubMed
  8. Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med. 2009;361:1067–1074. - PubMed
  9. U.S. Food & Drug Administration. Center for drug evaluation and research and center for biologics evaluation and research. Pharmacol Rev. Application Number: 125057/0 Adalimumab (LU 200134). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/BLA_125057_S000_HUMIRA_PHARMR.PDF. Accessed December 20, 2019. - PubMed
  10. Ryu YS, Park SH, Kim JM, et al. A case of leukoencephalopathy associated with adalimumab-treated rheumatoid arthritis and a review of literature. Rheumatol Int. 2012;32:3481–3485. - PubMed
  11. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531–1534. - PubMed
  12. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862–2869. - PubMed
  13. Cinque P, Koralnik IJ, Gerevini S, et al. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis. 2009;9:625–636. - PubMed
  14. Hayashi Y, Kimura A, Kato S, et al. Progressive multifocal leukoencephalopathy and CD4+ T-lymphocytopenia in a patient with Sjogren syndrome. J Neurol Sci. 2008;268:195–198. - PubMed
  15. Akiyama M, Takahashi T, Nomura S, et al. Progressive multifocal leukoencephalopathy in a patient with multiple myeloma. Int J Hematol. 2010;92:186–189. - PubMed
  16. Berger JR, Malik V, Lacey S, et al. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. J Neurovirol. 2018;24:323–331. - PubMed
  17. Ho PR, Koendgen H, Campbell N, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16:925–933. - PubMed
  18. Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol. 2007;6:431–441. - PubMed

Publication Types